"国立研究開発法人国立精神・神経医療研究センター病院は、脳の病」（神経疾患）と「こころの病」（精神疾患）は別な病気ではなく、多くの部分で重なり合うところが多いため、一つ一つ病気としてではなく一人の患者さん（トータル）として治療していくことが大切です。当院は両者の専門家をそろえたユニークな病院であり、高度なだけでなく全人的な医療を目指します。NCNP病院は、1940年にわが国初の国立精神療養所として開設されて以来、精神・神経・筋疾患と発達障害の克服を目指すナショナルセンター病院として歩んでいます。 武蔵野の東京ドーム4つ分の敷地に囲まれたNCNP病院には、四季折々の花と緑を楽しめる豊かな環境があります。自然に囲まれた安心できるキャンパスで、一人一人の患者さんやそのご家族を中心に、医師、看護師、リハビリテーション職員、薬剤師、検査技師、医療連携福祉担当職員、さらに事務職員も含めて院内すべての職員がお互いに協力して、最高の医療を提供いたします。患者さんやご家族に「来てよかった」と言っていただけることをする、が私たちの合言葉です。 精神・神経疾患の臨床研究を推進する中核的役割を担い、基礎研究の成果を医療に生かし、高度な医療を優しく提供します。そして、未来の医療を担う人材を育て、情報を全国に発信します。治験などをつうじて患者さんやご家族のご協力をいただきながら、国内外の多くの研究施設等と連携して、病因解明や新たな治療法の開発を進めることが私たちの使命の一つです。"

During the past decade, National Center of Neurology and Psychiatry conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 20 clinical trials were completed, i.e. on average, 39.2% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 18 clinical trials were completed. i.e. 85.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Center of Neurology and Psychiatry" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "Boehringer Ingelheim" with 7 trials sponsored, "National Center of Neurology and Psychiatry, Japan" with 7 trials sponsored, "Pfizer" with 4 trials sponsored and "Takeda" with 4 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Center of Neurology and Psychiatry" #1 collaborator was "Nippon Shinyaku Co., Ltd." with 4 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Hoffmann-La Roche" with 1 trials as a collaborator, "Jain Foundation" with 1 trials as a collaborator and "Japan Medical Association" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "National Center of Neurology and Psychiatry" are "Duchenne Muscular Dystrophy" (13 trials), "Schizophrenia" (6 trials), "Alzheimer Disease" (4 trials), "Nervous System Diseases" (3 trials) and "Neuromyelitis Optica Spectrum Disorder" (3 trials). Many other conditions were trialed in "National Center of Neurology and Psychiatry" in a lesser frequency.

Most popular intervention types in "National Center of Neurology and Psychiatry" are "Drug" (49 trials), "Biological" (4 trials), "Other" (4 trials), "Behavioral" (2 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (30 trials), "Soticlestat" (3 trials), "BI 425809 dose 1" (2 trials), "BI 425809 dose 2" (2 trials) and "BI 425809 dose 3" (2 trials). Other intervention names were less common.

The vast majority of trials in "National Center of Neurology and Psychiatry" are 42 trials for "All" genders, 15 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "National Center of Neurology and Psychiatry". undefined are not yet recruiting, 13 are recruiting, 8 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 24 completed trials in National Center of Neurology and Psychiatry, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in National Center of Neurology and Psychiatry, 4 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".